Eventide Asset Management LLC Lowers Stock Holdings in United Therapeutics Corporation $UTHR

Eventide Asset Management LLC trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR) by 24.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,004 shares of the biotechnology company’s stock after selling 15,237 shares during the quarter. Eventide Asset Management LLC’s holdings in United Therapeutics were worth $22,903,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of UTHR. Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics in the third quarter worth about $317,617,000. Norges Bank bought a new position in shares of United Therapeutics in the fourth quarter worth approximately $293,418,000. Baillie Gifford & Co. bought a new position in shares of United Therapeutics in the fourth quarter worth approximately $157,390,000. Balyasny Asset Management L.P. increased its position in shares of United Therapeutics by 863.9% in the second quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock worth $43,886,000 after purchasing an additional 136,883 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of United Therapeutics by 108.1% in the fourth quarter. Victory Capital Management Inc. now owns 228,383 shares of the biotechnology company’s stock worth $111,280,000 after purchasing an additional 118,628 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $545.96 on Friday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm’s 50 day simple moving average is $566.75 and its two-hundred day simple moving average is $521.34. The stock has a market capitalization of $23.17 billion, a P/E ratio of 20.15, a PEG ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the business earned $6.63 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. As a group, equities analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 634,984 shares of company stock worth $358,175,202 in the last quarter. 8.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, Raymond James Financial assumed coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.